Brain metastases (brain mets) are frequent in metastatic melanoma patients. The aim of this study was to investigate the morphology and progression pattern of brain mets in melanoma patients treated with BRAF inhibitors (BRAFi) compared with patients who did not receive targeted therapy (BRAFi group and control group). The number and size of brain mets were compared between a baseline and a comparative MRI at progression. The number of brain mets was grouped into seven number classes (N = 1-4, N = 5-10, N = 11-20, N = 21-30, N = 31-40, N = 41-50, and N > 50) and its difference was reported as the change of class that occurred. The mean size of the newly developed lesions was determined by representative measurements and the evolution of three persisting target lesions was assessed on the basis of modified RECIST criteria. Of 96 patients studied, 42 were in the BRAFi group and 54 were in the control group. Patients under BRAFi treatment had a significantly greater increase in the number of brain mets, where the median change of class for the BRAFi compared with the control group was 2 versus 0 (P < 0.01). The mean size of the new lesions was smaller in the BRAFi group. Preexisting target lesions did not show any prominent or different patterns of how they evolved in either group. Brain mets in patients treated with BRAFi showed a progression pattern characterized by a high propensity to disseminate, which might reflect an in-vivo manifestation of phenotype switching in response to targeted therapy, with a predominance of the invasive/migratory tumor cell phenotype. Drivers of invasiveness may present promising targets for therapeutic interventions. Melanoma Res
Introduction
Melanoma has a high propensity to metastasize to the brain. Up to 20% of melanoma patients present with brain metastases (brain mets) at diagnosis of stage IV and ∼ 40-50% ultimately develop them during the course of their disease [1, 2] . Overall, central nervous system involvement heralds a poor prognosis [3, 4] .
The introduction of immunotherapy and targeted therapy has changed the standard of care in the treatment of advanced melanoma. On the basis of the discovery that 40-60% of melanomas harbor a targetable BRAF V600 mutation, a new era of mitogen-activated protein kinase inhibitors (MAPKi) has been established [5] . Selectively targeted BRAF-inhibitors (BRAFi, e.g. vemurafenib, dabrafenib) have shown impressive clinical efficacy and have led to improved survival in patients with V600-mutated metastatic melanoma [6, 7] . Subsequently, the superiority of concurrent BRAF/MEK inhibition (e.g. vemurafenib/cobimetinib, dabrafenib/trametinib) has been reported in several clinical trials [8, 9] . In patients with brain mets, evidence of clinical activity of BRAFi is emerging [10, 11] , and currently available pooled data show a median overall survival of 7.9 months in this subset of patients [12] . Although a growing body of research is evaluating the efficacy and objective response rates of MAPKi to further determine their role in patients with brain mets (NCT01378975, NCT02230306, NCT02039947), the progression pattern in the brain and the influence of targeted therapies on this process have not been investigated very extensively so far. Therefore, the aim of this current study is to analyze the morphology and pattern of brain mets among melanoma patients treated with BRAFi and assess potential differences compared with patients who did not receive targeted therapies.
Hospital Zurich. Patients treated at our institution for stage IV melanoma with brain mets were identified from our Melanoma Registry, which records melanoma patients since 2008, and through our interdisciplinary oncology board meetings. Eligible patients were 18 years of age or older, had histologically confirmed stage IV cutaneous or mucosal melanoma, and at least one intracranial tumor lesion. The study protocol was approved by the local ethics committee (EK647/KEK-ZH-Nr. 2014-0193).
Patients were divided into two groups on the basis of whether (BRAFi group) or not (control group) they received targeted therapy. Targeted therapy included BRAFi monotherapy and/or BRAFi/MEKi combination therapy. Electronic medical records were reviewed for demographical and clinicopathological parameters. Data extraction included age, sex, primary tumor characteristics, mutational status, and details of systemic and locoregional brain therapies.
Definition of baseline and comparative study
To analyze the change in pattern in brain mets in patients exposed to BRAFi versus those not exposed, two contrast-enhanced MRI studies of the brain were compared. The baseline (t 1 ) and comparative image (t 2 ) for the two different groups were defined as follows: in the BRAFi group, brain mets evolution under treatment exposure to targeted therapy was examined. Accordingly, the last MRI obtained immediately before treatment initiation with BRAFi (baseline image) was compared with the last MRI before termination of BRAFi treatment (comparative image). In the control group, each patient's initial and terminal brain mets status was examined. This was illustrated by the MRI of first radiographical brain mets detection (baseline image) and the last available brain MRI in a patient's disease course (comparative image). To investigate how persisting lesions evolved during the evaluation period, up to three target lesions present and (20) Age is reported in years as median age and range. All other variables are reported in n (%). a K601E, D594H. Variables are reported in n (%).
Immunotherapy included ipilimumab, nivolumab, pembrolizumab, and tremeliumab. Multikinase inhibitor therapy included sorafenib, pazopanib, and imatinib. BRAFi, BRAF inhibitor; Chemo, chemotherapy; Immuno, immunotherapy; mki, multikinase inhibitor therapy. Combination of resection and radiation 3 (7) 24 (44) Variables are reported in n (%). t 1 -t 2 represents the evaluation period between the baseline and the comparative image. BRAFi, BRAF inhibitor; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy.
reproducibly measurable in both baseline and comparative images were defined, and their largest sum of diameter was measured. The difference in the largest sum of diameter was calculated and then reported as stable disease, progressive disease, partial response, or complete response according to a modified application of the RECIST 1.1 criteria. An estimate of the mean size of the newly developed brain mets at t 2 was made by measuring up to five lesions considered to be representative of the new lesion's predominant size. All analyses were carried out by the same investigator. 
Results

Patient, disease, and treatment characteristics
A total of 96 patients were included for analysis and patient baseline characteristics are reported in Table 1 .
In the BRAFi group, 32 (76%) patients received targeted therapy upfront, whereas the remaining 24% had other systemic therapies before BRAFi treatment. In the control group, 20 (37%) patients received systemic therapies before the evaluation period. Details on the systemic therapies patients received before the evaluation period are shown for each group in Table 2 .
During the evaluation period, patients in the BRAFi group received either BRAFi monotherapy, in 83% (all vemurafenib, N = 35), combination therapy, in 7% (vemurafenib/cobimetinib, N = 1, encorafenib/binimetinib, N = 2), or monotherapy with vemurafenib, followed by combination therapy, in 10% (vemurafenib/cobimetinib, N = 2, dabrafenib/trametinib, N = 2). Patients in the control group received systemic therapy, 89%, during the evaluation period (chemotherapy alone, N = 21, immunotherapy alone, N = 13, multikinase inhibitor alone, N = 1, chemotherapy and immunotherapy, N = 7, chemotherapy and multikinase inhibitor, N = 6).
Locoregional brain therapies including surgical resection, radiation therapy (stereotactic radiosurgery and/or wholebrain radiation therapy), or a combination of both surgical resection and radiation therapy were more frequently used in the control group than in the BRAFi group (87 and 43%, respectively). Details on brain therapies administered during t 1 and t 2 are shown for each group in Table 3 .
The median observation time between the baseline and comparative image (t 1 -t 2 ) was similar in both groups, with 5.8 (range: 1.6-20.7) months in the BRAFi group and 5.3 (range: 0.6-38.2) months in the control group. The median treatment duration with targeted therapy in the BRAFi group was 5.8 (range: 1.9-24.4) months.
Number of brain mets
The majority of patients in both the BRAFi and control groups had 1-4 brain mets at baseline (62 and 78%, respectively). More patients in the BRAFi group already had more than 10 brain mets at baseline (31 vs. 9%). The distributions of brain mets present at baseline and comparative images are shown for each group in Fig. 1 .
In the comparative MRI, there was a significantly higher increase in the number of brain mets in the BRAFi compared with the control group (P < 0.01). The majority (60%) of the patients in the BRAFi group showed an increase of more than one number class, whereas only 15% in the control group showed an increase of more than one number class (Fig. 2a) . The patients in the BRAFi group showed a median increase of two number classes, whereas patients in the control group remained in the same class (median class switch of 2 vs. 0, P < 0.01, Fig. 2b ).
No change in class or even a reduction in class was more frequently observed in the control group than in the BRAFi group (44 and 26% vs. 23 and 2%, respectively).
Size of brain mets
Pre-existing target lesions did not show any prominent or different patterns of how they evolved in either group. A higher percentage of patients in the BRAFi group showed a partial response of their target lesions (29 vs. 13%). Fourteen (26%) patients in the control group showed a complete response associated with a reduction of class, but only one patient in the BRAFi group.
New emerging lesions measured at t 2 were in general smaller in the BRAFi group (mean size 5.9 mm) compared with the control group (mean size 7.4 mm). This difference was not statistically significant (P = 0.15).
Discussion
BRAF-targeted therapies have become a very important component in the treatment of patients with BRAFmutated metastatic melanoma, including patients with brain mets. To our knowledge, this is the first study to focus on the morphology and pattern of brain mets progression in melanoma patients treated with BRAFi compared with patients not exposed to such therapies. Our data indicated that patients under BRAFi frequently showed a marked increase in the number of brain mets during targeted therapy. MRIs at the time of comparison often showed more multiple and smaller brain lesions than before initiation of BRAFi treatment at baseline and, in some cases, showed innumerable contrastenhancing punctate lesions (Fig. 3) , indicative of a miliary, disseminated distribution pattern of brain mets. In the control group, such intracranial disease courses were far less likely to occur and the majority of patients did not even experience an increase in the number class of present brain mets at all.
These results are intriguing because they suggest an unusual dissemination pattern of brain mets under BRAFi treatment and consequently, the question arises whether this pattern is unique to the brain or might reflect a general effect of BRAFi treatment. Azer et al.
[13] investigated patterns of response and progression assessed by disease-site (intracranial vs. extracranial) in 23 patients with melanoma brain mets treated with dabrafenib. They concluded that there was no dominant site (intracranial vs. extracranial) or pattern (new vs. existing lesions) of disease progression and site-specific response was concordant in 71% [13] . In contrast, Seifert et al. [14] found in a retrospective study that response to vemurafenib was indeed dependent on the anatomical site and complete or partial response was particularly low in the brain. In addition, the brain was the most common site for new metastases to develop [14] . Similarly, there was considerable remission of extracerebral disease, but intracranial metastases developed or progressed in a series of patients [15] .
Recently, many researchers have intensively investigated the various mechanisms driving tumor progression and drug resistance in melanoma. One model that has been able to link the changes observed in cellular behavior and molecular biology during metastatic progression and has increasingly been invoked is the phenotype switching model. It is based on the characterization of different gene expression signatures that define two populations of melanoma cells, distinctive by showing either a more invasive or a proliferative phenotype [16, 17] . These transcriptional states are interchangeable programs between which melanoma cells switch back and forth, catalyzing repeated episodes of dissemination and tumorigenesis, where the dynamics of this process are markedly influenced by local microenvironmental factors [17, 18] . The transition from a proliferative to an invasive phenotype shares many features of epithelial-tomesenchymal transformation and is associated with a characteristic cell morphology switch from predominantly rounded to elongated cells [19] [20] [21] . In line with other researchers, we believe that melanoma cells use phenotype switching as an escape mechanism to targeted therapy as it has been observed that proliferative melanoma cells can acquire invasive features upon MAPKi, and as a result, not only become less susceptible to growth inhibition but also have greater ability to metastasize [19, 22, 23] . Apart from this, there is growing literature stating an increased activation of the AKT-PI3K pathway in melanoma brain mets compared with other distant metastatic sites [15, 24] , and melanoma cells stimulated by astrocyte-conditioned medium showed higher AKT activation and invasiveness, adding evidence that extrinsic factors in the brain microenvironment may induce these brain-specific molecular alterations [14, 15, 25] . This supports the hypothesis that the tumor microenvironment differs between the body and the brain and that this type of resistance mechanism to BRAFi could be specific to the brain. Yet, in autopsy studies of some of our BRAF-mutated melanoma patients, we have observed a similar disseminated metastatic spread in organs other than the brain, including the lung and the liver.
There are limitations in this study and its retrospective nature is certainly one of them. Tailored to each patient's individual needs, the two groups are heterogeneous in the systemic and local brain treatments received before and during the evaluation period. Apart from the fact that the group allocation was primarily dependent on the patient's BRAF mutational status, t 1 and t 2 represented logical time points on the basis of exposure to a specific therapy in the BRAFi group, whereas a slightly different timeline was observed in the control group. In addition, the semiquantitative approach by grouping the number of brain mets in classes and reporting class switches instead of exact numbers and differences limits accuracy. Still, we are convinced that our results show clear and reliable differences between the two groups.
Conclusion
Patients under BRAFi showed a distinct pattern of progression in the brain. It seems that BRAFi therapy can facilitate metastatic dissemination in the brain, leading to a miliary pattern of brain mets presenting with multiple small punctate lesions in MRIs. This might reflect an invivo manifestation of phenotype switching in melanoma progression and suggests the predominance of an invasive/migratory tumor cell phenotype. Therefore, drivers of invasiveness may present promising targets for therapeutic interventions.
